Torbjörn Tomson1, Dina Battino2, Erminio Bonizzoni2, John Craig2, Dick Lindhout2, Emilio Perucca2, Anne Sabers2, Sanjeev V Thomas2, Frank Vajda2. 1. From the Department of Clinical Neuroscience (T.T.), Karolinska Institutet; Department of Neurology (T.T.), Karolinska University Hospital, Stockholm, Sweden; Epilepsy Center, Department of Neurophysiology and Experimental Epileptology (D.B.), Fondazione IRCCS Istituto Neurologico Carlo Besta; Department of Clinical Science and Community (E.B.), Section of Medical Statistics, Biometry and Epidemiology "G.A. Maccacaro," Faculty of Medicine and Surgery, University of Milan, Italy; Belfast Health and Social Care Trust (J.C.), Belfast, UK; Department of Genetics (D.L.), University Medical Center Utrecht; Stichting Epilepsie Instellingen Nederland (SEIN) (D.L.), Heemstede, the Netherlands; Department of Internal Medicine and Therapeutics (E.P.), University of Pavia; Clinical Trial Center (E.P.), IRCCS Mondino Foundation, Pavia, Italy; The Epilepsy Clinic, Department of Neurology (A.S.), Rigshospitalet-Blegdamsvej, University State Hospital, Copenhagen, Denmark; Department of Neurology (S.V.T.), Sree Chitra Tirunal Institute of Medical Sciences and Technology, Trivandrum, Kerala State, India; Departments of Medicine and Neurology (F.V.), University of Melbourne and Monash University; and Royal Melbourne Hospital (F.V.), Australia. torbjorn.tomson@sll.se. 2. From the Department of Clinical Neuroscience (T.T.), Karolinska Institutet; Department of Neurology (T.T.), Karolinska University Hospital, Stockholm, Sweden; Epilepsy Center, Department of Neurophysiology and Experimental Epileptology (D.B.), Fondazione IRCCS Istituto Neurologico Carlo Besta; Department of Clinical Science and Community (E.B.), Section of Medical Statistics, Biometry and Epidemiology "G.A. Maccacaro," Faculty of Medicine and Surgery, University of Milan, Italy; Belfast Health and Social Care Trust (J.C.), Belfast, UK; Department of Genetics (D.L.), University Medical Center Utrecht; Stichting Epilepsie Instellingen Nederland (SEIN) (D.L.), Heemstede, the Netherlands; Department of Internal Medicine and Therapeutics (E.P.), University of Pavia; Clinical Trial Center (E.P.), IRCCS Mondino Foundation, Pavia, Italy; The Epilepsy Clinic, Department of Neurology (A.S.), Rigshospitalet-Blegdamsvej, University State Hospital, Copenhagen, Denmark; Department of Neurology (S.V.T.), Sree Chitra Tirunal Institute of Medical Sciences and Technology, Trivandrum, Kerala State, India; Departments of Medicine and Neurology (F.V.), University of Melbourne and Monash University; and Royal Melbourne Hospital (F.V.), Australia.
Abstract
OBJECTIVE: Changes in prescribing patterns of antiepileptic drugs (AEDs) in pregnant women with epilepsy would be expected to affect the risk of major congenital malformations (MCMs). To test this hypothesis, we analyzed data from an international pregnancy registry (EURAP). METHODS: EURAP is an observational prospective cohort study designed to determine the risk of MCMs after prenatal exposure to AEDs. The Cochrane-Armitage linear trend analysis was used to assess changes in AED treatment, prevalence of MCMs, and occurrence of generalized tonic-clonic seizures (GTCs) over 3 time periods: 2000-2005 (n = 4,760), 2006-2009 (n = 3,599), and 2010-2013 (n = 2,949). RESULTS: There were pronounced changes in the use of specific AEDs over time, with a decrease in the use of valproic acid and carbamazepine and an increase in the use of lamotrigine and levetiracetam. The prevalence of MCMs with monotherapy exposure decreased from 6.0% in 2000-2005 to 4.4% in 2010-2013. The change over time in MCM frequency after monotherapy exposure showed a significant linear trend in the crude analysis (p = 0.0087), which was no longer present after adjustment for changes in AED treatment (p = 0.9923). There was no indication of an increase over time in occurrence of GTCs during pregnancy. CONCLUSIONS: There have been major changes in AED prescription patterns over the years covered by the study. In parallel, we observed a significant 27% decrease in the prevalence of MCMs. The results of adjusting the trend analysis for MCMs for changes in AED treatment suggest that changes in prescription patterns played a major role in the reduction of teratogenic events.
OBJECTIVE: Changes in prescribing patterns of antiepileptic drugs (AEDs) in pregnant women with epilepsy would be expected to affect the risk of major congenital malformations (MCMs). To test this hypothesis, we analyzed data from an international pregnancy registry (EURAP). METHODS: EURAP is an observational prospective cohort study designed to determine the risk of MCMs after prenatal exposure to AEDs. The Cochrane-Armitage linear trend analysis was used to assess changes in AED treatment, prevalence of MCMs, and occurrence of generalized tonic-clonic seizures (GTCs) over 3 time periods: 2000-2005 (n = 4,760), 2006-2009 (n = 3,599), and 2010-2013 (n = 2,949). RESULTS: There were pronounced changes in the use of specific AEDs over time, with a decrease in the use of valproic acid and carbamazepine and an increase in the use of lamotrigine and levetiracetam. The prevalence of MCMs with monotherapy exposure decreased from 6.0% in 2000-2005 to 4.4% in 2010-2013. The change over time in MCM frequency after monotherapy exposure showed a significant linear trend in the crude analysis (p = 0.0087), which was no longer present after adjustment for changes in AED treatment (p = 0.9923). There was no indication of an increase over time in occurrence of GTCs during pregnancy. CONCLUSIONS: There have been major changes in AED prescription patterns over the years covered by the study. In parallel, we observed a significant 27% decrease in the prevalence of MCMs. The results of adjusting the trend analysis for MCMs for changes in AED treatment suggest that changes in prescription patterns played a major role in the reduction of teratogenic events.
Authors: Page B Pennell; Jacqueline A French; Ryan C May; Elizabeth Gerard; Laura Kalayjian; Patricia Penovich; Evan Gedzelman; Jennifer Cavitt; Sean Hwang; Alison M Pack; Maria Sam; John W Miller; Steffanie H Wilson; Carrie Brown; Angela K Birnbaum; Kimford J Meador Journal: N Engl J Med Date: 2020-12-24 Impact factor: 91.245
Authors: Ushma Mehta; Mariette Smith; Emma Kalk; Helen Hayes; Annoesjka Swart; Lawrence Tucker; Renier Coetzee; Andrew Boulle; Marc Blockman Journal: Drug Saf Date: 2021-01 Impact factor: 5.606
Authors: John Samuel Bass; Anney H Tuo; Linh T Ton; Miranda J Jankovic; Paarth K Kapadia; Catharina Schirmer; Vaishnav Krishnan Journal: Front Neurosci Date: 2020-11-06 Impact factor: 4.677
Authors: Richard H Finnell; Carlo Donato Caiaffa; Sung-Eun Kim; Yunping Lei; John Steele; Xuanye Cao; Gabriel Tukeman; Ying Linda Lin; Robert M Cabrera; Bogdan J Wlodarczyk Journal: Front Genet Date: 2021-05-10 Impact factor: 4.599